Free Trial
LON:STX

Shield Therapeutics (STX) Share Price, News & Analysis

GBX 2.05
0.00 (0.00%)
(As of 06/14/2024 ET)
Today's Range
2.01
2.19
50-Day Range
1.23
2.50
52-Week Range
1.06
12.85
Volume
680,897 shs
Average Volume
5.20 million shs
Market Capitalization
£16.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
STX stock logo

About Shield Therapeutics Stock (LON:STX)

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

STX Stock Price History

STX Stock News Headlines

Shield Therapeutics (LON:STX) Shares Up 9.1%
Shield Therapeutics (LON:STX) Shares Down 9.6%
Shield Therapeutics PLC STX
Shield Therapeutics plc (STX.L)
Shield Therapeutics to present at NPWH conference this month
Shield Therapeutics CFO Hans-Peter Rudolf to Step Down
See More Headlines
Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

Net Income
£-48,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£7.40 million
Cash Flow
GBX 0.32 per share
Book Value
GBX 4 per share

Miscellaneous

Free Float
N/A
Market Cap
£15.72 million
Optionable
Not Optionable
Beta
0.90
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Gregory P. Madison (Age 57)
    CEO & Executive Director
    Comp: $678k
  • Dr. Christian Schweiger M.D. (Age 58)
    Ph.D., Co-Founder & Non Executive Director
    Comp: $45k
  • Mr. Santosh Shanbhag (Age 46)
    Chief Financial Officer
  • Ms. Lucy Kate Huntington-Bailey
    General Counsel & Company Secretary
  • Ms. Suzanne Wood
    Group HR Director
  • Ms. Carol Akinola
    Head of Pharmacovigilance & Medical Information
  • Mr. Andrew Hurley (Age 55)
    Chief Commercial Officer
  • Kate Armanetti
    Senior Director of People & Culture

STX Stock Analysis - Frequently Asked Questions

How have STX shares performed in 2024?

Shield Therapeutics' stock was trading at GBX 6.70 at the beginning of the year. Since then, STX stock has decreased by 69.4% and is now trading at GBX 2.05.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX).

How do I buy shares of Shield Therapeutics?

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:STX) was last updated on 6/14/2024 by MarketBeat.com Staff

From Our Partners